Wall Street analysts expect that STERIS plc (NYSE:STE) will report earnings per share of $1.80 for the current quarter, Zacks reports. Three analysts have provided estimates for STERIS’s earnings. The lowest EPS estimate is $1.78 and the highest is $1.81. STERIS posted earnings of $1.64 per share in the same quarter last year, which indicates a positive year over year growth rate of 9.8%. The business is expected to issue its next earnings report after the market closes on Tuesday, May 18th.
According to Zacks, analysts expect that STERIS will report full year earnings of $6.31 per share for the current year, with EPS estimates ranging from $6.28 to $6.33. For the next year, analysts forecast that the business will report earnings of $6.97 per share, with EPS estimates ranging from $6.91 to $7.00. Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow STERIS.
A number of equities research analysts have recently weighed in on STE shares. JMP Securities boosted their price objective on shares of STERIS from $217.00 to $235.00 and gave the company an “outperform” rating in a report on Tuesday. Zacks Investment Research downgraded STERIS from a “buy” rating to a “hold” rating and set a $227.00 price target on the stock. in a research note on Tuesday, April 27th. Raymond James restated a “hold” rating on shares of STERIS in a research note on Wednesday, January 20th. Finally, KeyCorp upped their target price on STERIS from $224.00 to $227.00 and gave the company an “overweight” rating in a research report on Wednesday, March 17th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. STERIS presently has a consensus rating of “Buy” and a consensus target price of $223.80.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vantage Consulting Group Inc acquired a new position in shares of STERIS during the 4th quarter worth approximately $25,000. Exchange Traded Concepts LLC lifted its holdings in STERIS by 278.4% during the fourth quarter. Exchange Traded Concepts LLC now owns 140 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 103 shares in the last quarter. Allred Capital Management LLC acquired a new stake in shares of STERIS in the first quarter valued at about $33,000. Kinloch Capital LLC purchased a new stake in shares of STERIS during the fourth quarter worth about $36,000. Finally, Veriti Management LLC acquired a new position in shares of STERIS during the 4th quarter worth about $38,000. 90.01% of the stock is owned by institutional investors.
STERIS stock traded down $1.21 during mid-day trading on Friday, reaching $197.78. 602,549 shares of the company traded hands, compared to its average volume of 629,771. The firm’s fifty day moving average is $204.01 and its two-hundred day moving average is $190.65. The company has a market capitalization of $16.88 billion, a price-to-earnings ratio of 40.12 and a beta of 0.59. STERIS has a fifty-two week low of $146.12 and a fifty-two week high of $216.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.64 and a quick ratio of 2.00.
STERIS Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Read More: Stock Market – What is a circuit breaker?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.